Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma.
Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB, Kleespies A, Angele MK, Hartwig W, Bruns CJ, Kirchner T, Werner J, Heinemann V, Boeck S. Kruger S, et al. Among authors: modest dp. J Cancer Res Clin Oncol. 2016 Dec;142(12):2585-2591. doi: 10.1007/s00432-016-2264-7. Epub 2016 Sep 14. J Cancer Res Clin Oncol. 2016. PMID: 27629876 Free PMC article.
Inhibition of Vascular Endothelial Growth Factor Protects against the Development of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Wild-Type but Not in CD39-Null Mice.
Knitter S, Duwe G, Beierle AS, Pesthy S, Ritschl PV, Hillebrandt KH, Arnold A, Malinka T, Modest DP, Bahra M, Pratschke J, Sauer IM, Schmelzle M, Andreou A. Knitter S, et al. Among authors: modest dp. Cancers (Basel). 2022 Dec 5;14(23):5992. doi: 10.3390/cancers14235992. Cancers (Basel). 2022. PMID: 36497474 Free PMC article.
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.
Ambrosini M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M, Kim S, Coutzac C, Perkins G, Alouani E, Marmorino F, Pernot S, Sinicrope FA, Elez E, Parent P, Cremolini C, Pietrantonio F, Lonardi S, Gallois C, Taieb J. Ambrosini M, et al. Eur J Cancer. 2024 Oct;210:114290. doi: 10.1016/j.ejca.2024.114290. Epub 2024 Aug 22. Eur J Cancer. 2024. PMID: 39216175
Viscoelastic properties of colorectal liver metastases reflect tumour cell viability.
Skrip LM, Moosburner S, Tang P, Guo J, Görner S, Tzschätzsch H, Brüggemann K, Walter KA, Hosse C, Fehrenbach U, Arnold A, Modest D, Krenzien F, Schöning W, Malinka T, Pratschke J, Papke B, Käs JA, Sack I, Sauer IM, Hillebrandt KH. Skrip LM, et al. J Transl Med. 2024 Aug 16;22(1):774. doi: 10.1186/s12967-024-05559-z. J Transl Med. 2024. PMID: 39152426 Free PMC article.
Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer.
Anker MS, Khan MS, Nikolski A, Porthun J, Arshad MS, Hadzibegovic S, Lena A, Kretzler L, Hella JL, Witkowski M, Rieger K, Ahn J, Modest DP, Keller U, Bullinger L, Totzeck M, Mahabadi AA, Rassaf T, Buchmann N, Attanasio P, Zeller T, Karakas M, Tocchetti CG, Wilkenshoff U, Cleland JGF, von Haehling S, Butler J, Landmesser U. Anker MS, et al. Among authors: modest dp. Eur J Heart Fail. 2025 Aug 6. doi: 10.1002/ejhf.3744. Online ahead of print. Eur J Heart Fail. 2025. PMID: 40767389
Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
Taieb J, Modest DP, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Gravalos C, Bragagnoli AC, Barboux V, Roby L, Amellal N, Prager GW. Taieb J, et al. Among authors: modest dp. Eur J Cancer. 2025 Sep 9;227:115644. doi: 10.1016/j.ejca.2025.115644. Epub 2025 Jul 12. Eur J Cancer. 2025. PMID: 40694985 Free article. Clinical Trial.
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Giessen C, Stintzing S, Laubender RP, Ankerst DP, Schulz C, Moosmann N, Modest DP, Schalhorn A, von Weikersthal LF, Heinemann V. Giessen C, et al. Among authors: modest dp. Clin Colorectal Cancer. 2011 Dec;10(4):317-24. doi: 10.1016/j.clcc.2011.03.027. Epub 2011 May 12. Clin Colorectal Cancer. 2011. PMID: 21729676 Clinical Trial.
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, Mayerle J, Bangerter M, Denzlinger C, Sieber M, Teschendorf C, Freiberg-Richter J, Schulz C, Modest DP, Moosmann N, Aubele P, Heinemann V. Giessen C, et al. Among authors: modest dp. BMC Cancer. 2011 Aug 23;11:367. doi: 10.1186/1471-2407-11-367. BMC Cancer. 2011. PMID: 21861888 Free PMC article. Clinical Trial.
173 results